Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Zinck, Suzanne
Bagnell, Alexa
Bond, Kenneth
and
Newton, Amanda S.
2009.
The Cochrane library and the treatment of major depression in children and youth: an overview of reviews.
Evidence-Based Child Health: A Cochrane Review Journal,
Vol. 4,
Issue. 4,
p.
1336.
Lam, Raymond W.
Lönn, Sara Larsson
and
Despiégel, Nicolas
2010.
Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
International Clinical Psychopharmacology,
Vol. 25,
Issue. 4,
p.
199.
Leonard, Brian
and
Taylor, David
2010.
Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression.
Journal of Psychopharmacology,
Vol. 24,
Issue. 8,
p.
1143.
Wang, Junling
Liu, Xianchen
and
Mullins, C. Daniel
2011.
Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Current Medical Research and Opinion,
Vol. 27,
Issue. 7,
p.
1303.
Kennedy, Sidney H.
Young, Allan H.
and
Blier, Pierre
2011.
Strategies to achieve clinical effectiveness: Refining existing therapies and pursuing emerging targets.
Journal of Affective Disorders,
Vol. 132,
Issue. ,
p.
S21.
Dell’Osso, Bernardo
Palazzo, M. Carlotta
Oldani, Lucio
and
Altamura, A. Carlo
2011.
The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects.
CNS Neuroscience & Therapeutics,
Vol. 17,
Issue. 6,
p.
723.
Almasio, Piero L.
Babudieri, Sergio
Barbarini, Giorgio
Brunetto, Maurizia
Conte, Dario
Dentico, Pietro
Gaeta, Giovanni B.
Leonardi, Claudio
Levrero, Massimo
Mazzotta, Francesco
Morrone, Aldo
Nosotti, Lorenzo
Prati, Daniele
Rapicetta, Maria
Sagnelli, Evangelista
Scotto, Gaetano
and
Starnini, Giulio
2011.
Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates).
Digestive and Liver Disease,
Vol. 43,
Issue. 8,
p.
589.
Sanglier, T.
Milea, D.
Saragoussi, D.
and
Toumi, M.
2012.
Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10mg.
European Psychiatry,
Vol. 27,
Issue. 4,
p.
250.
Zhong, Huailing
Haddjeri, Nasser
and
Sánchez, Connie
2012.
Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action.
Psychopharmacology,
Vol. 219,
Issue. 1,
p.
1.
Bose, Anjana
Tsai, Joyce
and
Li, Dayong
2012.
Early Non-Response in Patients with Severe Depression.
Clinical Drug Investigation,
Vol. 32,
Issue. 6,
p.
373.
Bradley, Andrew J
and
Lenox-Smith, Alan J
2013.
Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials.
Journal of Psychopharmacology,
Vol. 27,
Issue. 8,
p.
740.
Nguyen, Hai T
Guiard, Bruno P
Bacq, Alexandre
David, Denis J
David, Indira
Quesseveur, Gaël
Gautron, Sophie
Sanchez, Connie
and
Gardier, Alain M
2013.
Blockade of the high‐affinity noradrenaline transporter (NET) by the selective 5‐HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice.
British Journal of Pharmacology,
Vol. 168,
Issue. 1,
p.
103.
Citrome, L.
2013.
Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?.
International Journal of Clinical Practice,
Vol. 67,
Issue. 11,
p.
1089.
Jain, Rakesh
Chen, Dalei
Edwards, John
and
Mathews, Maju
2014.
Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
Current Medical Research and Opinion,
Vol. 30,
Issue. 2,
p.
263.
Souery, Daniel
Calati, Raffaella
Papageorgiou, Konstantinos
Juven-Wetzler, Alzbeta
Gailledreau, Joël
Modavi, David
Sentissi, Othman
Pitchot, William
Papadimitriou, George N.
Dikeos, Dimitris
Montgomery, Stuart
Kasper, Siegfried
Zohar, Joseph
Serretti, Alessandro
and
Mendlewicz, Julien
2015.
What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
The World Journal of Biological Psychiatry,
Vol. 16,
Issue. 7,
p.
472.
2016.
Diagnosis and Treatment of Mental Disorders Across the Lifespan.
p.
957.
Camacho, Mariam B.
and
Anastasio, Thomas J.
2017.
Computational Model of Antidepressant Response Heterogeneity as Multi-pathway Neuroadaptation.
Frontiers in Pharmacology,
Vol. 8,
Issue. ,
Shah, Drishti
Vaidya, Varun
Patel, Amit
Borovicka, Mary
and
Goodman, Monica-Holiday
2017.
Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression.
Quality of Life Research,
Vol. 26,
Issue. 4,
p.
969.
Cappetta, Kiley
Beyer, Chad
Johnson, Jessica A.
and
Bloch, Michael H.
2018.
Meta-analysis: Risk of dry mouth with second generation antidepressants.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 84,
Issue. ,
p.
282.
Kaur, Harneet
Sidana, Ajeet
and
Singh, ThiyamKiran
2019.
Comparison of efficacy and tolerability of escitalopram and venlafaxine in treatment-naïve patients with unipolar nonpsychotic depression: Is there a need to revisit the prescription patterns?.
Journal of Mental Health and Human Behaviour,
Vol. 24,
Issue. 1,
p.
15.